1.Cheung, W.-H., et al., Prevention of Age-related Neuromuscular Junction Degeneration in Sarcopenia by Low-magnitude High-frequency Vibration. 2022.
2.Leung, K., et al., Effects of 18-month low-magnitude high-frequency vibration on fall rate and fracture risks in 710 community elderly—a cluster-randomized controlled trial. Osteoporosis international, 2014. 25: p. 1785-1795.
3.Wu, S., et al., Effects of vibration therapy on muscle mass, muscle strength and physical function in older adults with sarcopenia: a systematic review and meta-analysis. European Review of Aging and Physical Activity, 2020. 17: p. 1-12.
4.Wang, J., et al., Vibration and β‐hydroxy‐β‐methylbutyrate treatment suppresses intramuscular fat infiltration and adipogenic differentiation in sarcopenic mice. Journal of Cachexia, Sarcopenia and Muscle, 2020. 11(2): p. 564-577.
5.Cruz-Jentoft, A.J., et al., Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age and ageing, 2010. 39(4): p. 412-423.
6.Rolland, Y., et al., Sarcopenia: its assessment, etiology, pathogenesis, consequences and future perspectives. The Journal of nutrition, health and aging, 2008. 12(7): p. 433-450.
7.Zhao, H.-F., J. Wang, and S.-S. Tony To, The phosphatidylinositol 3-kinase/Akt and c-Jun N-terminal kinase signaling in cancer: Alliance or contradiction? International journal of oncology, 2015. 47(2): p. 429-436.
8.Raney, M.A. and L.P. Turcotte, Regulation of contraction-induced FA uptake and oxidation by AMPK and ERK1/2 is intensity dependent in rodent muscle. American Journal of Physiology-Endocrinology and Metabolism, 2006. 291(6): p. E1220-E1227.